Treatment of psychiatric disturbances in common hyperkinetic movement disorders

References

• Martino D, Espay AJ, Fasano A, et al., eds. Disorders of movement. A guide to diagnosis and treatment. Berlin Heidelberg: Springer Verlag; 2016.
   Google Scholar
• Stamelou M, Edwards MJ, Hallett M, et al. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain. 2012;135:1668–1681.
   PubMed Web of Science ®Google Scholar
• Kumar A, Trescheri W, Byleri D. Tourette syndrome and comorbid neuropsychiatric conditions. Curr Dev Disord Rep. 2016;3:217–221.
   PubMedGoogle Scholar
• Van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–1418.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala K, Pal PK. The non-motor features of essential tremor: a primary disease feature or just a secondary phenomenon? Tremor Other Hyperkinet Mov. 2014;4. DOI:10.7916/D8D798MZ
   PubMedGoogle Scholar
• van Den Dool J, Tijssen MAJ, Koelman JHTM, et al. Determinants of disability in cervical dystonia. Parkinsonism Rel Disord. 2016;32:48–53.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE, Gulisano M, et al. Clinical correlates of quality of life in Tourette syndrome. Dev Mol Child Neurol. 2009;51:218–227.
   PubMed Web of Science ®Google Scholar
• Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in essential tremor. Mov Disord. 2001;16:914–920.
   PubMed Web of Science ®Google Scholar
• Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–873.
   PubMed Web of Science ®Google Scholar
• Defazio G, Esposito M, Abbruzzese G, et al. The Italian dystonia registry: rationale, design and preliminary findings. Neurol Sci. 2017;38(5):819–825.
   PubMed Web of Science ®Google Scholar
• Jinnah HA, Berardelli A, Comella C, et al. The focal dystonias: current views and challenges for future research. Mov Disord. 2013;28(7):926–943.
   PubMed Web of Science ®Google Scholar
• Berman BD, Junker J, Shelton E, et al. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017;88:595–602.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Berardelli I, Moretti G, et al. Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord. 2010;25:459–465.
   PubMed Web of Science ®Google Scholar
• Smit M, Kuiper A, Han V, et al. Psychiatric comorbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Rel Disord. 2016;30:7–12.
   PubMed Web of Science ®Google Scholar
• Lencer R, Steinlechner S, Stahlberg J, et al. Primary focal dystonia: evidence for distinct neuropsychiatric and personality profiles. J Neurol Neurosurg Psychiatry. 2009;80:1176–1179.
   PubMed Web of Science ®Google Scholar
• Lehn G, Mellick R. Boyle, Psychiatric disorders in idiopathic-isolated focal dystonia. J Neurol. 2014;261:668–674.
   PubMed Web of Science ®Google Scholar
• Gundel H, Wolf A, Xidara V, et al. High psychiatric comorbidity in spasmodic torticollis: a controlled study. J Nerv Ment Dis. 2003;191:465–473.
   PubMed Web of Science ®Google Scholar
• Voon V, Butler TR, Ekanayake V, et al. Psychiatric symptoms associated with focal hand dystonia. Mov Disord. 2010;25:2249–2252.
   PubMed Web of Science ®Google Scholar
• Gundel H, Busch R, Ceballos-Baumann A, et al. Psychiatric comorbidity in patients with spasmodic dysphonia: a controlled study. J Neurol Neurosurg Psychiatry. 2007;78:1398–1400.
   PubMed Web of Science ®Google Scholar
• Berardelli I, Ferrazzano G, Pasquini M, et al. Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Res. 2015;30:229:583–585.
   Web of Science ®Google Scholar
• Antelmi E, Stamelou M, Liguori R, et al. Nonmotor symptoms in dopa-responsive dystonia. Mov Disord Clin Pract. 2015 Jul 22;2(4):347–356. eCollection 2015 Dec. Review. PubMed PMID: 30363518; PubMed Central PMCID: PMC 6178708.
   PubMed Web of Science ®Google Scholar
• Zoons E, Jan Booij J, Delnooz CCS, et al. Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. J Neurol Neurosurg Psychiatry. 2018;89:579–585.
   PubMed Web of Science ®Google Scholar
• Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007;22:95–100.
   PubMed Web of Science ®Google Scholar
• Barahona-Corre B, Bugalho P, Guimaraes J, et al. Obsessive-compulsive symptoms in primary focal dystonia: a controlled study. Mov Disord. 2011;26:2274–2278.
   PubMed Web of Science ®Google Scholar
• Liow NY, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol. 2016;20(1):100–107.
   PubMed Web of Science ®Google Scholar
• Faircloth S, Reid S. A cognitive-behavioural approach to the management of idiopathic cervical dystonia. J Behav Ther Exp Psychiatry. 2006;37:239–246.
   PubMed Web of Science ®Google Scholar
• Spencer J, Goetsch VL, Brugnoli RJ, et al. Behavior therapy for spasmodic torticollis: a case study suggesting a causal role for anxiety. J Behav Ther Exp Psychiatry. 1991;22:305–311.
   PubMed Web of Science ®Google Scholar
• Cury RG, Kalia SK, Shah BB, et al. Surgical treatment of dystonia. Expert Rev Neurother. 2018;18(6):477–492.
   PubMed Web of Science ®Google Scholar
• de Gusmao CM, Pollak LE, Shama N. Neuropsychological and psychiatric outcome of GPi-deep brain stimulation in dystonia. Brain Stimul. 2017;10:994e996.
   Web of Science ®Google Scholar
• Cohen SC, Leckman JF, Bloch MH. Clinical assessment of Tourette syndrome and tic disorders. Neurosci Biobehav Rev. 2013;37:997–1007.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
   Google Scholar
• Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain. 2000;123:425–462.
   PubMed Web of Science ®Google Scholar
• Diniz JB, Rosario-Campos MC, Hounie AG, et al. Chronic tics and Tourette syndrome in patients with obsessive–compulsive disorder. J Psych Res. 2006;40:487–493.
   Google Scholar
• Fabbrini G, Pasquini M, Aurilia C, et al. A large Italian family with Gilles de la Tourette syndrome: clinical study and analysis of the SLITRK1 gene. Mov Disord. 2007;22:2229–2234.
   PubMedGoogle Scholar
• Pasquini M, Fabbrini G, Berardelli I, et al. Psychopathological features of obsessive–compulsive disorder in an Italian family with Gilles de la Tourette syndrome not linked to the SLITRK1 gene. Psychiatry Res. 2008;161:109–111.
   PubMed Web of Science ®Google Scholar
• George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles-De-La-Tourette syndrome. Hum Psychopharmacol Clin Exp. 1993;8:327–334.
   Web of Science ®Google Scholar
• Giakas WJ. Risperidone treatment for a Tourette’s disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1097–1098.
   PubMed Web of Science ®Google Scholar
• Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62(1):50–56.
   PubMed Web of Science ®Google Scholar
• Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41:330–336.
   PubMed Web of Science ®Google Scholar
• Gerasch S, Kanaan AS, Jakubovski E, et al. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci. 2016;10:416.
   PubMed Web of Science ®Google Scholar
• Riddle M, Hardin M, King R, et al. Fluoxetine treatment of children and adolescents with Tourette’s and OCD: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1990;29:45–49.
   PubMed Web of Science ®Google Scholar
• Ratzoni G, Hermesh H, Brandt N, et al. Clomipramine efficacy for tics, obsessions, and compulsions in Tourette’s syndrome and obsessive-compulsive disorder: a case study. Biol Psychiatry. 1990;27(1):95–98.
   PubMed Web of Science ®Google Scholar
• Iancu I, Kotler M, Bleich A, et al. Clomipramine efficacy for Tourette syndrome and major depression: a case study. Biol Psychiatry. 1995 Sep 15;38(6):407–409.
   PubMed Web of Science ®Google Scholar
• Roessner V, Kerstin J, Plessen KJ, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173–196.
   PubMed Web of Science ®Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067–1074.
   PubMed Web of Science ®Google Scholar
• Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527–536.
   PubMed Web of Science ®Google Scholar
• Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941–1949.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11(4):470–481.
   PubMed Web of Science ®Google Scholar
• Gilbert DL, Zhang J, Lipps TD, et al. Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement. Clin Neurophysiol. 2007;118(8):1835–1841.
   PubMed Web of Science ®Google Scholar
• Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95(1):74–81.
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002;59(7):649–656.
   PubMed Web of Science ®Google Scholar
• Masi G, Gagliano A, Siracusano R, et al. Aripiprazole in children with Tourette’s disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol. 2012;22(2):120–125.
   PubMed Web of Science ®Google Scholar
• Quezada J, Keith A. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs. 2018;32(1):33–45.
   PubMed Web of Science ®Google Scholar
• Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am. 2010;33:557–577.
   PubMed Web of Science ®Google Scholar
• March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2007;61:344–347.
   PubMed Web of Science ®Google Scholar
• Skarphedinsson G, Compton S, Thomsen PH, et al. Tics moderate sertraline, but not cognitive-behavior therapy response in pediatric obsessive-compulsive disorder patients who do not respond to cognitive-behavior therapy. J Child Adolesc Psychopharmacol. 2015;25(5):432–439.
   PubMed Web of Science ®Google Scholar
• O’Connor KP, Laverdure A, Taillon A, et al. Cognitive behavioral management of Tourette’s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther. 2009;47:1090–1095.
   PubMed Web of Science ®Google Scholar
• Woods DW, Piacentini JC, Scahill L, et al. Behavior therapy for tics in children: acute and long-term effects on psychiatric and psychosocial functioning. J Child Neurol. 2011;26:858–865.
   PubMed Web of Science ®Google Scholar
• Azrin NH, Peterson AL. Treatment of Tourette syndrome by habit reversal: A waiting list control group comparison. Behav Ther. 1990;21:305–318.
   Web of Science ®Google Scholar
• Wilhelm S, Deckersbach T, Coffey BJ, et al. Habit reversal versus supportive psychotherapy for Tourette’s disorder: a randomized controlled trial. Am J Psychiatry. 2003;160:1175–1177.
   PubMed Web of Science ®Google Scholar
• O’connor KP, Lavoie ME, Stip E, Borgeat F, Laverdure A. Cognitive-behaviour therapy and skilled motor performance in adults with chronic tic disorder. Neuropsychol Rehabil Neuropsychol Rehabil. 2008;18(1):45–64.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Peterson AL, Piacentini J, et al. Randomized trial of behaviour therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69:795–803.
   PubMed Web of Science ®Google Scholar
• Yates R, Edwards K, King J, et al. Habit reversal training and educational group treatments for children with Tourette syndrome: A preliminary randomised controlled trial. Behaviour Res Ther. 2016;80:43–50.
   PubMed Web of Science ®Google Scholar
• Whittington C, Pennant M, Kendall T, et al. Practitioner review: treatments for Tourette syndrome in children and young people - a systematic review. J Child Psychol Psychiatry. 2016;57(9):988–1004.
   PubMed Web of Science ®Google Scholar
• Ricketts EJ, Goetz AR, Capriotti MR, et al. A randomized waitlist-controlled pilot trial of voice over Internet protocol-delivered behavior therapy for youth with chronic tic disorders. J Telemd Telecare. 2016;22:153–162.
   PubMed Web of Science ®Google Scholar
• Deckersbach T, Rauch S, Buhlmann U, et al. Habit reversal versus supportive psychotherapy in Tourette’s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther. 2006;44:1079–1090.
   PubMed Web of Science ®Google Scholar
• Verdellen CW, Keijsers GP, Cath DC, et al. Exposure with response prevention versus habit reversal in Tourette’s syndrome: a controlled study. Behav Res Ther. 2004;42:501–511.
   PubMed Web of Science ®Google Scholar
• Verdellen CW, Hoogduin CA, Keijsers GP. Tic suppression in the treatment of Tourette’s syndrome with exposure therapy: the rebound phenomenon reconsidered. Mov Disord. 2007 15;22(11):1601–1606.
   PubMed Web of Science ®Google Scholar
• Verdellen CW, Hoogduin CA, Kato BS, et al. Habituation of premonitory sensations during exposure and response prevention treatment in Tourette’s syndrome. Behav Modif. 2008;32(2):215–227.
   PubMed Web of Science ®Google Scholar
• Buse J, Kirschbaum C, Leckman JF, et al. The modulating role of stress in the onset and course of Tourette’s syndrome: a review. Behav Modif. 2014;38(2):184–216.
   PubMed Web of Science ®Google Scholar
• Reese HE, Vallejo Z, Rasmussen J, et al. Mindfulness-based stress reduction for Tourette syndrome and chronic tic disorder: a pilot study. J Psychosom Res. 2015;78(3):293–298.
   PubMed Web of Science ®Google Scholar
• Hawksley J, Cavanna AE, Nagai Y. The role of autonomic system in Tourette syndrome. Front Neurosci. 2015 27;9:117.
   PubMed Web of Science ®Google Scholar
• Nagai Y, Cavanna A, Critchley HD. Influence of sympathetic autonomic arousal on tics: implications for a therapeutic behavioral intervention for Tourette syndrome. J Psychosom Res. 2009;67:599–605.
   PubMed Web of Science ®Google Scholar
• Zhuo C, Li L. The application and efficacy of combined neurofeedback therapy and imagery training in adolescents with Tourette syndrome. J Child Neurol. 2014;29(7):965–968.
   PubMed Web of Science ®Google Scholar
• Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers amd prospects for therapies. Nat Rev Neurol. 2014;10:204–216.
   PubMed Web of Science ®Google Scholar
• Orth M, Handley OJ, Schwenke C, et al. Observing Huntington’s disease: the European Huntington’s disease network’s REGISTRY. J Neurol Neurosurg Psychiatry. 2011;82(12):1409–1412.
   PubMed Web of Science ®Google Scholar
• Moulton CD, Hopkins WP, Bevan-Jones WR. Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease. Mov Disord. 2014;29:1556–1561.
   PubMed Web of Science ®Google Scholar
• Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46–50.
   PubMed Web of Science ®Google Scholar
• Raja M, Soleti F, Bentivoglio AR. Lithium treatment in patients with Huntington disease and suicidal behavior. J Clin Psychopharmacol. 2013;336:819–821.
   Google Scholar
• Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484–487.
   PubMed Web of Science ®Google Scholar
• Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord. 2014;29:401–405.
   PubMed Web of Science ®Google Scholar
• Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat. 2009;51:4.
   Google Scholar
• Bonelli RM. Mirtazapine in suicidal Huntington’s disease. Ann Pharmacother. 2003;37:452.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Wustenberg T, McLean T, et al. Bupropion for the treatment of apathy in Huntington’s disease: A multicenter, randomised, double-blind, placebo controlled, prospective crossover trial. PLoS One. 2017 Mar 21;12(3):e0173872.
   PubMed Web of Science ®Google Scholar
• Anderson K, Craufurd D, Edmondson MC, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington’s disease. PLoS Curr. 2011;3:RRN1261.
   PubMedGoogle Scholar
• Squitieri F, Cannella M, Porcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2011;14:69–72.
   Google Scholar
• Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–72.
   PubMed Web of Science ®Google Scholar
• Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington’s disease. Eur J Neurol. 2002;9:182–183.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington’s disease. Am J Geriatr Psychiatry. 1998;6:347–349.
   PubMed Web of Science ®Google Scholar
• Lin W-C, Chou Y-H. Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry. 2008;165:1207–1208.
   PubMed Web of Science ®Google Scholar
• De Marchi N, Daniele F, Ragone M. Fluoxetine in the treatment of Huntington’s disease. Psychopharmacology (Berl). 2001;153:264–266.
   PubMed Web of Science ®Google Scholar
• Royuela Rico A, Gil-Verona JA, Macias Fernandez JA. A case of obsessive symptoms in Huntington’s disease. Actas Esp Psiquiatr. 2003;31:367–370.
   PubMed Web of Science ®Google Scholar
• Patzold T, Brüne M. Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol. 2002;5(3):216–219.
   Google Scholar
• Ranen NG, Lipsey JR, Treisman G, et al. Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1996;8:338–340.
   PubMed Web of Science ®Google Scholar
• Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington’s disease and other neurological disorders. Psychosomatics. 1997;38:389–391.
   PubMed Web of Science ®Google Scholar
• Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington’s disease. Am J Psychiatry. 1994;151:1097.
   PubMed Web of Science ®Google Scholar
• Findling RL. Treatment of aggression in juvenile-onset Huntington’s disease with buspirone. Psychosomatics. 1993;34:460–461.
   PubMed Web of Science ®Google Scholar
• Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington’s disease with olanzapine and valproate. N Engl J Med. 2000;343:973–974.
   PubMed Web of Science ®Google Scholar
• Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington’s disease. PLoS Curr. 2011;3:RRN1259.
   PubMedGoogle Scholar
• Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20(1):1–3.
   PubMed Web of Science ®Google Scholar
• Priller J, Ecker D, Landwehrmeyer B, et al. A Europe-wide assessment of current medication choices in Huntington’s disease. Mov Disord. 2008;23(12):1788.
   PubMed Web of Science ®Google Scholar
• Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. From the task force on tremor of the international Parkinson and movement disorder society. Mov Disord. 2018;33(1):75–87.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Berardelli I, Falla M, et al. Psychiatric disorders in patients with essential tremor. Parkinsonism Rel Disord. 2012;18:971–973.
   PubMed Web of Science ®Google Scholar
• Monin JK, Gutierrez J, Kellner S, et al. Psychological suffering in essential tremor: a study of patients and those who are close to them. Tremor Other Hyperkinet Mov (N Y). 2017;7:526.
   PubMed Web of Science ®Google Scholar
• Louis ED, Cosentino S, Huey ED. Depressive symptoms can amplify embarrassment in essential tremor. J Clin Mov Disord. 2016 Jul 15;3: 11.
   PubMedGoogle Scholar
• Ozel-Kizil ET, Akbostanci MC, Ozguven HD, et al. Secondary social anxiety in hyperkinesias. Mov Disord. 2008;23:641–645.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Jurewicz EC, Applegate LM, et al. Personality in essential tremor: further evidence of non-motor manifestations of the disease. J Neurol Neurosurg Psychiatr. 2004;75:958–961.
   PubMed Web of Science ®Google Scholar
• Huey ED, Cosentino S, Chapman S, et al. Self-report depressive symptoms are dissociated from tremor severity in essential tremor. Parkinsonism Relat Disord. 2018;50:87–93.
   PubMed Web of Science ®Google Scholar
• Smeltere L, Kuzņecovs V, Erts R. Depression and social phobia in essential tremor and Parkinson’s disease. Brain Behav. 2017 Aug 2;7(9):e00781.
   PubMed Web of Science ®Google Scholar
• Zappia M, Albanese A, Bruno E, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian movement disorders association. J Neurol. 2013;260:714–740.
   PubMed Web of Science ®Google Scholar
• Chugh S, Chhabria A, Jung S, et al. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract. 2018;24(1):15–20.
   PubMed Web of Science ®Google Scholar
• Magid M, Reichenberg JS, Poth PE, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837–844.
   PubMed Web of Science ®Google Scholar
• Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006 May;32(5):645–649. discussion 649–50.
   PubMed Web of Science ®Google Scholar
• Elble RJ, Shih L, Cozzens JW. Surgical treatments for essential tremor. Expert Rev Neurother. 2018;18(4):303–321.
   PubMed Web of Science ®Google Scholar
• Bernstein CJ, Ellard DR, Davies G, et al. Behavioural interventions for people living with adult-onset primary dystonia: a systematic review. BMC Neurol. 2016 Mar 22;16:40.
   PubMed Web of Science ®Google Scholar
• Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36:589–596.
   PubMed Web of Science ®Google Scholar
• Erenberg G. The relationship between tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol. 2005 Dec;12(4):217–221.
   PubMedGoogle Scholar
• Gadow KD, Sverd J, Nolan EE, et al. Immediate‐release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:840–848.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Martino D. Guanfacine for the treatment of attention deficit hyperctivity disorder in children and adolescents. Expert Rev Neurother. 2015;15(4):347–354.
   PubMed Web of Science ®Google Scholar
• Poulton A. Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder. Expert Rev Neurother. 2006;6(4):551–561.
   PubMedGoogle Scholar
• Arnsten AFT. The use of a-2A adrenergic agonists for the treatment of attention-deficit hyperctivity disorder. Expert Rev Neurother. 2014;15(11):1601–1610.
   Google Scholar
• Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurotherap. 2018;18:125–137.
   PubMed Web of Science ®Google Scholar
• Fründt O, Woods D, Ganos C. Behavioral therapy for Tourette syndrome and chronic tic disorders. Neurol Clin Pract. 2017;7(2):148–156.
   PubMedGoogle Scholar
• Verdellen C, van de Griendt J, Hartmann A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry. 2011;20:197–207.
   PubMed Web of Science ®Google Scholar
• Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-based approaches? Mov Disord. 2014;29:1404–1413.
   PubMed Web of Science ®Google Scholar
• Shannon KM, Fraint A. Therapeutic advances in Huntington’s disease. Mov Disord. 2015;30:1539–1546.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12:2701–2720.
   PubMed Web of Science ®Google Scholar
• Unti E, Mazzucchi S, Palermo G, et al. Antipsychotic drugs in Huntington’s disease. Expert Rev Neurother. 2017 Mar;17(3):227–237.
   PubMed Web of Science ®Google Scholar
• Nance MA. Comprehensive care in Huntington’s disease: a physician’s perspective. Brain Res Bull. 2007;72(2–3):175–178.
   PubMed Web of Science ®Google Scholar